Innovation, Research
EG427: treating neurogenic bladder with precision gene therapy
… of defective herpes simplex virus vectors (HSV-1). They produce a controlled version of the gene to treat patients … SATT Paris-Saclay in 2016. This has enabled the team to conduct pre-clinical studies, obtain proof of concept and file … in animal models, as well as that it is able to reach a production capacity which meets regulatory requirements. EG427 …Published on: Thu 09/09/2021 - 10:44